Cost pressures associated with the development of new
medications are at an all-time high for the pharmaceutical
industry. Drug development costs in general are rising and
particularly so within therapeutic categories, for certain
disease states where highly targeted and costly therapies such
as biologics show promise. Kunal Jaiswal, Vice President,
Strategic Development Solutions, Clinical Supply Services at
Catalent, aims to compare the traditional supply model with
the demand-led model.